IO is a rescue therapy for patients with relapsed or refractory CD22-positive precursor B-cell acute lymphoblastic leukemia (R/R CD22-positive BCP-ALL). The gene discussed is CD22; the disease is B-cell acute lymphoblastic leukemia.